产品中心 / 产品类型 / 细胞系&裂解液 / KO细胞裂解液

ERBB2 Knockout HeLa Cell Lysate, Homozygous (RM02053)

Genome sequence analysis of PCR products from parental (WT) and ERBB2 knockout (KO) HeLa cells, using sanger sequencing.

All(1)|
货号: RM02053
促销价:   ¥4700
抗体定制服务咨询

文献引用 (0)

详细信息

靶点
ERBB2
细胞系
HeLa
突变描述
ERBB2 Knockout HeLa Cell Line is engineered from HeLa cell line with Gene-Editing technology.
Allele-1:1bp insertion in exon2
Allele-2:47bp deletion in exon2

Mammalian cells such as human, rat and mouse cells are normally diploid with two alleles.
Homozygote: both alleles were knocked out, mRNA has no signal, no expression of proteins.
Heterozygote: only one allele was knocked out, the mRNA transcript levels was decreased compared to wild type, and the protein expression levels was also lower than that of the wild type.
敲除验证
Sanger Sequencing
产品组成
1 vial parental cell Lysate and 1 vial knockout cell Lysate
裂解液量
50μL, 2μg/μL.
使用方法
To be used as WB control. Lysate is supplied in 1× SDS sample buffer (2% SDS, 60 mM
Tris-HCl pH 6.8, 10% Glycerol, 0.02% Bromophenol blue, 60 mM beta-mercaptoethanol).
Lysate should be boiled for 3 - 5 minutes before loading onto gel.
物种
Human
保存条件
Lysate is stable for 12 months when stored at -20℃. Minimizing freeze-thaw cycles.
运输条件
4℃

背景信息

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]

>